Phase 2 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have given their informed consent to take part in the study
- People who are at least 18 years old
- People diagnosed with non-small cell lung cancer (a common type of lung cancer) — whether it is localised, has spread to nearby areas, or has spread further in the body — and who are already planned to have surgery to remove or take a small sample (biopsy) of at least one tumour. The tumour also needs to meet a minimum size requirement depending on its type and location (confirm with trial site for details)
- People who have taken part in this study before may be considered again, as long as all the entry requirements are met and none of the reasons for exclusion apply at the time of re-entry
Who may not be able to join:
- People whose general health and ability to carry out daily activities is significantly limited, as measured by a standard medical scale called the ECOG scale (a score of 3 or higher, meaning largely confined to bed or chair for more than half of waking hours)
- People who are currently pregnant
- People who are currently breastfeeding
- People who have a serious active infection at the time of the study
- People who have another serious illness or a problem with how a major organ is working, which the study doctor believes could put the person at risk or affect the study results
- People who are unlikely to be able to follow the requirements of the study
- People who are unwilling or unable to give informed consent
- People who are considered at increased risk of death due to a serious pre-existing illness
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Tony Lahoutte, MD, PhD, Universitair Ziekenhuis Brussel
Phone: +32 2 477 6013
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Correlation of uptake of 68GaNOTA-Anti-MMR-VHH2 in a NSCLC lesion before surgery with the immunohistological MMR-staining of the excised lesion.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.